Posted on Thursday, 21/Nov/2019 Posted by admin

At today’s Annual General Meeting of Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, the Board will make the following statement:

Diurnal’s primary focus remains on progressing Chronocort® and Alkindi®, our two lead products, which are potentially valuable treatment options with a combined opportunity of over $3bn for diseases resulting from cortisol deficiency in the US and Europe.

Diurnal remains on track to submit two key regulatory filings during Q4 2019, namely a Marketing Authorisation Application submission for Chronocort® in Europe and a New Drug Application submission for Alkindi® in the US. This follows the two regulatory filings already made for Alkindi® during 2019 by our partners Medison and Emerge in Israel and Australia, respectively.

Recent pricing work has reinforced the significant commercial potential for Alkindi® and Chronocort® in the US; Diurnal’s discussions with US partners around its late-stage cortisol deficiency pipeline continue to advance and it expects to conclude a licensing deal during H1 2020. Diurnal is also progressing licensing discussions in other territories and expects to announce further progress in due course.

The commercial roll out of Alkindi® in Europe continues to progress, with sales for the year to date in line with expectations.

Diurnal also continues to progress its early-stage pipeline, with positive headline results from the Company’s DITEST™ (native oral testosterone formulation) Phase I proof-of-concept clinical trial, announced yesterday.

For further information, please visit or contact:

Diurnal Group plc +44 (0)20 3727 1000
Martin Whitaker, Chief Executive Officer 
Richard Bungay, Chief Financial Officer 

Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker) +44 (0) 20 7886 2500
Corporate Finance: Freddy Crossley, Emma Earl
Corporate Broking: James Stearns

Cantor Fitzgerald Europe (Joint Broker) +44 (0) 20 7894 7000
Corporate Finance: Phil Davies, Will Goode, Michael Boot
Healthcare Equity Sales: Andrew Keith

FTI Consulting +44 (0)20 3727 1000
Simon Conway 
Victoria Foster Mitchell

Notes to Editors

About Diurnal Group plc
Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

For further information about Diurnal, please visit

Date of Preparation: November 2019       Code: CORP-GB-0043